P3 Health Partners (PIII)
(Delayed Data from NSDQ)
$0.62 USD
+0.01 (1.70%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $0.63 +0.01 (1.55%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth F Momentum B VGM
Price, Consensus and EPS Surprise
PIII 0.62 +0.01(1.70%)
Will PIII be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PIII based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PIII
P3 Health Partners Inc. (PIII) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
3 Medical Info Systems Stocks to Buy as Industry Rebounds
PIII: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights P3 Health Partners, Talkspace and Augmedix
3 Medical Info Systems Stocks to Buy as Industry Trends Improve
Here's Why P3 Health Partners Inc. (PIII) is Poised for a Turnaround After Losing -28.57% in 4 Weeks
Other News for PIII
P3 Health Partners Schedules Second Quarter 2024 Earnings Release and Conference Call
P3 Health Partners Forms Strategic Partnership with Innovaccer to Drive Value-Based Care and Patient Experience
7 F-Rated Growth Stocks to Avoid Right Now: June 2024
P3 Health Partners files to sell 134.77M shares of Class A common for holders
P3 Health Partners: Moving In The Right Direction In 2024